Invited Commentary : The Prevalent New-User Design in Pharmacoepidemiology-Challenges and Opportunities
© The Author(s) 2020. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
The prevalent new-user design includes a broader study population than the traditional new-user approach that is frequently used in pharmacoepidemiologic research. In an article appearing in this issue (Am J Epidemiol. 2021;190(7):1341-1348), Webster-Clark et al. describe the treatment initiator types included in the prevalent new-user design and contrast the causal questions assessed using a prevalent new-user design versus a new-user design. They further applied a series of simulation studies showing the importance of accounting for treatment history in addition to time since initiation of the comparator in the prevalent new-user design. In this commentary, we put their findings in the broader context with a discussion of the strengths and limitations of the prevalent new-user design and settings where it would be most useful. The prevalent new-user design and new-user design both address unique questions of clinical and public health importance. Real-world evidence generated by pharmacoepidemiologic research is increasingly being used by regulators and other knowledge users to inform their decision-making. Understanding the causal questions addressed by different designs is crucial in this process; the study by Webster-Clark et al. represents an important step in addressing this issue.
| Errataetall: |
CommentOn: Am J Epidemiol. 2021 Jul 1;190(7):1341-1348. - PMID 33350433 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:190 |
|---|---|
| Enthalten in: |
American journal of epidemiology - 190(2021), 7 vom: 01. Juli, Seite 1349-1352 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Filion, Kristian B [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Comment |
|---|
| Anmerkungen: |
Date Completed 23.08.2021 Date Revised 23.08.2021 published: Print CommentOn: Am J Epidemiol. 2021 Jul 1;190(7):1341-1348. - PMID 33350433 Citation Status MEDLINE |
|---|
| doi: |
10.1093/aje/kwaa284 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319150488 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319150488 | ||
| 003 | DE-627 | ||
| 005 | 20231225170836.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/aje/kwaa284 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1063.xml |
| 035 | |a (DE-627)NLM319150488 | ||
| 035 | |a (NLM)33350439 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Filion, Kristian B |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Invited Commentary |b The Prevalent New-User Design in Pharmacoepidemiology-Challenges and Opportunities |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.08.2021 | ||
| 500 | |a Date Revised 23.08.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentOn: Am J Epidemiol. 2021 Jul 1;190(7):1341-1348. - PMID 33350433 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2020. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a The prevalent new-user design includes a broader study population than the traditional new-user approach that is frequently used in pharmacoepidemiologic research. In an article appearing in this issue (Am J Epidemiol. 2021;190(7):1341-1348), Webster-Clark et al. describe the treatment initiator types included in the prevalent new-user design and contrast the causal questions assessed using a prevalent new-user design versus a new-user design. They further applied a series of simulation studies showing the importance of accounting for treatment history in addition to time since initiation of the comparator in the prevalent new-user design. In this commentary, we put their findings in the broader context with a discussion of the strengths and limitations of the prevalent new-user design and settings where it would be most useful. The prevalent new-user design and new-user design both address unique questions of clinical and public health importance. Real-world evidence generated by pharmacoepidemiologic research is increasingly being used by regulators and other knowledge users to inform their decision-making. Understanding the causal questions addressed by different designs is crucial in this process; the study by Webster-Clark et al. represents an important step in addressing this issue | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Comment | |
| 650 | 4 | |a pharmacoepidemiology | |
| 650 | 4 | |a prevalent new-user design | |
| 650 | 4 | |a study design | |
| 700 | 1 | |a Yu, Ya-Hui |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of epidemiology |d 1965 |g 190(2021), 7 vom: 01. Juli, Seite 1349-1352 |w (DE-627)NLM000012327 |x 1476-6256 |7 nnns |
| 773 | 1 | 8 | |g volume:190 |g year:2021 |g number:7 |g day:01 |g month:07 |g pages:1349-1352 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/aje/kwaa284 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 190 |j 2021 |e 7 |b 01 |c 07 |h 1349-1352 | ||